Apart from standard of care therapies, targeted therapy Cetuximab [10, 11] and immunotherapy against PD-1 and PD-L1 [12, 13] were first approved to treat advanced or recurrent HNSCC patients in 2006 and 2016, respectively. Here, CD274 is linked to head and neck squamous cell carcinoma.